Table 2.
Risk factors for high BKV viruria (≥ 107 copies/mL) post-HSCT.
| Factor | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| Hazard Ratio (95% CI) | P Value | Hazard Ratio (95% CI) | P Value | ||
| Age (years) | 1 year increment | 1.00 (0.98,1.03) | .828 | ||
| Female | ref: male | 0.61 (0.32,1.14) | .123 | ||
| Keratinocyte growth factor | ref: no | 0.74 (0.37,1.46) | .383 | ||
| Titers of BKV IgG | 4-fold increment | 1.30 (1.00, 1.70) | .054 | 1.43 (1.08, 1.89) | .013 |
| Mismatched donor | ref: matcheda | 1.01 (0.56,1.83) | .963 | ||
| T-cell depletion (TCD) | ref: non-TCD | 1.04 (0.58,1.87) | .903 | ||
| Cord blood | ref: peripheral blood stem cell | 1.13 (0.61, 2.12) | .692 | ||
| Ciprofloxacin use | ref: no | 0.90 (0.49, 1.64) | .731 | ||
| Pre-HSCT BKV ≥ 1.0×107 | ref: < 1.0×107 | 7.00 (2.80, 17.46) | <.001 | 7.26 (2.24, 23.48) | <.001 |
| Myeloablative or reduced intensity conditioning | ref: NMA | 0.41 (0.21,0.81) | .011 | 0.54 (0.25, 1.15) | .110 |
| Total body irradiation (TBI) | ref: no TBI | 0.83 (0.46,1.49) | .526 | ||
| CMV seropositive recipient | ref: seronegative | 1.31 (0.7,2.46) | .405 | ||
Abbreviations: HSCT, hematopoietic stem cell transplantation; KGF, keratinocyte growth factor; TCD, T-cell depletion; MA, myeloablative; RIC, reduced intensity; NMA, nonmyeloablative; TBI, total body irradiation; CMV, cytomegalovirus; ref, reference
a
Matched donor included matched related donor and matched unrelated donor.
*acute graft versus host disease, forcarnet treatment, and CMX001 treatment were not included since BK viruria occurred before these events.